CA2692549A1 - Optically active n-(alpha-mercaptopropionyl)glycine - Google Patents

Optically active n-(alpha-mercaptopropionyl)glycine Download PDF

Info

Publication number
CA2692549A1
CA2692549A1 CA 2692549 CA2692549A CA2692549A1 CA 2692549 A1 CA2692549 A1 CA 2692549A1 CA 2692549 CA2692549 CA 2692549 CA 2692549 A CA2692549 A CA 2692549A CA 2692549 A1 CA2692549 A1 CA 2692549A1
Authority
CA
Canada
Prior art keywords
glycine
mercaptopropionyl
preferred
alpha
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2692549
Other languages
English (en)
French (fr)
Inventor
Yong Wang
Cang Zhang
Zaijin Teng
Wenping Zhang
Jinye Qian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Sanhome Pharmaceutical Co Ltd
Original Assignee
Nanjing Sanhome Pharmaceutical Co., Ltd.
Yong Wang
Cang Zhang
Zaijin Teng
Wenping Zhang
Jinye Qian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN2007101374280A external-priority patent/CN101113141B/zh
Application filed by Nanjing Sanhome Pharmaceutical Co., Ltd., Yong Wang, Cang Zhang, Zaijin Teng, Wenping Zhang, Jinye Qian filed Critical Nanjing Sanhome Pharmaceutical Co., Ltd.
Publication of CA2692549A1 publication Critical patent/CA2692549A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA 2692549 2007-07-12 2007-12-28 Optically active n-(alpha-mercaptopropionyl)glycine Abandoned CA2692549A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2007101374280A CN101113141B (zh) 2006-07-19 2007-07-12 光学活性的N-(α-巯基丙酰基)甘氨酸
CN200710137428.0 2007-07-12
PCT/CN2007/003859 WO2009006773A1 (fr) 2007-07-12 2007-12-28 N- (α-mercaptopropionyle) glycine optiquement active

Publications (1)

Publication Number Publication Date
CA2692549A1 true CA2692549A1 (en) 2009-01-15

Family

ID=40228158

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2692549 Abandoned CA2692549A1 (en) 2007-07-12 2007-12-28 Optically active n-(alpha-mercaptopropionyl)glycine

Country Status (6)

Country Link
US (1) US20100204324A1 (ko)
EP (1) EP2181984A4 (ko)
JP (1) JP2010532767A (ko)
KR (1) KR20100031590A (ko)
CA (1) CA2692549A1 (ko)
WO (1) WO2009006773A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092402A1 (en) * 2018-10-30 2020-05-07 Harrow Health, Inc. Pharmaceutical compositions of tiopronin and methods for preparing thereof
CN113607840B (zh) * 2021-07-29 2023-06-30 山东京博农化科技股份有限公司 一种2-氯丙酸手性异构体的分离检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1491204A (fr) * 1962-08-10 1967-08-11 Santen Pharmaceutical Co Ltd Procédés pour la préparation des alpha-et beta mercaptopropionylglycocolle et de leurs dérivés
IT1098328B (it) * 1978-06-16 1985-09-07 Gargani Pietro Sale sodico della mercapropropionilglicina,processo per la sua preparazione e suoi impieghi terapeutici
JPH02204478A (ja) * 1989-02-02 1990-08-14 Santen Pharmaceut Co Ltd 光学異性体の分離方法
CN1305845C (zh) * 2005-05-16 2007-03-21 河南省新谊药业股份有限公司 用于治疗急慢性肝病的无水硫普罗宁钠及其制备方法
CN1969937B (zh) * 2005-11-22 2012-01-11 山东轩竹医药科技有限公司 一种治疗肝炎的药物组合物
CN1887859A (zh) * 2006-07-13 2007-01-03 武汉远大制药集团有限公司 硫普罗宁氨基酸盐及其制备方法

Also Published As

Publication number Publication date
EP2181984A4 (en) 2010-12-08
JP2010532767A (ja) 2010-10-14
WO2009006773A1 (fr) 2009-01-15
US20100204324A1 (en) 2010-08-12
KR20100031590A (ko) 2010-03-23
EP2181984A1 (en) 2010-05-05

Similar Documents

Publication Publication Date Title
US20230218595A1 (en) Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disorders
JP5885085B2 (ja) システアミン誘導体、および非アルコール性脂肪性肝炎の治療におけるその使用
CN101113141B (zh) 光学活性的N-(α-巯基丙酰基)甘氨酸
US20230322743A1 (en) Novel safrylamine derivatives having prodrug properties
CN104003975A (zh) 曲格列汀新的固态形式及其制备方法和用途
KR20180016437A (ko) 테노포비르 모노벤질 에스테르 포스파미드 전구약물, 이의 제조방법 및 용도
CN111635309B (zh) 一种新型解热镇痛药物及其制备方法和用途
JPS608000B2 (ja) アミノフエニル誘導体及び該誘導体を含有する生理活性剤
CA2876021C (en) Stabilized multi-functional antioxidant compounds and methods of use
CA2692549A1 (en) Optically active n-(alpha-mercaptopropionyl)glycine
CN105001195A (zh) R(+)-硫辛酸-l-赖氨酸盐的新晶型及其制备方法
US8871805B2 (en) Compound, composition and uses thereof
US7488846B2 (en) Pregabalin free of lactam and a process for preparation thereof
US20090318454A1 (en) Novel antioxidants and methods of treatment
CN116496205A (zh) 一种卡瑞斯汀的盐及其用途
US20230002343A1 (en) Left-handed bicyclic morpholine and salt thereof, preparation method therefor, pharmaceutical composition, and use
US20190151264A1 (en) Methods for treatment of prader-willi syndrome
US10556872B2 (en) Fatty acid synthase inhibitors and methods of use
Maspero et al. Synthesis and characterization of 13C labeled carnosine derivatives for isotope dilution mass spectrometry measurements in biological matrices
CN110218202A (zh) 一类n-苄基取代的氨基水杨酸2-坎醇酯的哌嗪衍生物及其药物用途
AU2020390812B2 (en) Left-handed bicyclic morpholine and salt thereof, preparation method therefor, pharmaceutical composition, and application
NZ226898A (en) Cysteine derivatives, preparation and pharmaceutical compositions thereof
CA3230557A1 (en) Ep4 antagonist compound as well as salt, polymorph, and use thereof
JP5201546B2 (ja) Ｎ‐アセチルシステイン抱合型胆汁酸、それを含有する医薬組成物及びその製造方法
CN116589522A (zh) 齐墩果酸c28葡萄糖三聚体衍生物及其应用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20121228